# Targeting Drugs with a Special Polysarcosine Polymer Chain

> This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.

- **Patent:** US 20250057964
- **Original title:** Ligand-drug-conjugate comprising a single molecular weight polysarcosine
- **Owner:** Mablink Bioscience SAS
- **Status:** Active
- **Times cited:** 0
- **Field:** pharmaceutical, biotech, materials

## What it does

This patent describes a Ligand-Drug-Conjugate (LDC) compound designed to deliver a drug, typically a cytotoxic drug, to a specific target in the body. The LDC (formula XV) uses a 'single molecular weight homopolymer' (Claim 1), which is preferably polysarcosine (Claim 2). This special polymer is connected to the drug via an 'orthogonal connector' (L), ensuring the polymer is positioned distinctly from the drug and its linker (X-D). The drug (D) can be released from the LDC using an optional 'cleavable moiety' (X), which might be triggered by conditions in the body, like acidic environments in lysosomes (Claim 9). For example, a cancer-targeting antibody (the ligand, Claim 5) could be attached to this polysarcosine chain, which then carries a chemotherapy drug directly to tumor cells, releasing it only when it reaches the target.

## What it does NOT cover

- Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).
- Does not cover LDCs where the polymer is not a 'homopolymer' (Claim 1), meaning it would not cover conjugates made with copolymers or other polymer types.
- Does not cover LDCs that use polymers other than polysarcosine as the single molecular weight homopolymer (Claim 2).
- Does not cover LDCs where the polymer is not in an 'orthogonal orientation' with respect to the drug and its linker (Claim 1).
- Does not cover drug conjugates where the drug is not attached via an 'orthogonal connector' (L) as defined (Claim 1).

## The clever bit

The clever bit is using a 'single molecular weight homopolymer,' specifically polysarcosine, as the polymer component in a drug conjugate. This provides precise control over the polymer's size and properties, which can improve drug stability and reduce variability in how the drug behaves in the body.

## Real-world examples

1. Antibody-drug conjugates (ADCs) in cancer therapy
2. Targeted drug delivery systems for chemotherapy
3. Biologics with enhanced half-life or reduced immunogenicity
4. Polysarcosine-based drug carriers

## Why it matters

Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.

## Frequently asked questions

### What does Targeting Drugs with a Special Polysarcosine Polymer Chain cover?

This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.

### Who owns patent US 20250057964?

This patent is owned by Mablink Bioscience SAS.

### When does this patent expire?

This patent is expected to expire on September 24, 2044, when the invention enters the public domain.

### What problem does this patent solve?

Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.

### What does this patent NOT cover?

Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).

**Full plain-English explainer:** https://patentbrief.org/patent/us/20250057964/ligand-drug-conjugate-comprising-a-single-molecular-weight-polysarcosine

**Original patent:** https://patents.google.com/patent/US20250057964

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Targeted Platinum Drugs for Cancer Treatment](https://patentbrief.org/patent/us/9884123/ligand-targeted-molecules-and-methods-thereof) — This patent describes a way to deliver platinum-based cancer drugs directly to tumor cells by attaching them to a special 'ligand' molecule that seeks out cancer cell markers.
- [Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds](https://patentbrief.org/patent/us/20210301031/napi2b-targeted-antibody-drug-conjugates-and-methods-of-use-thereof) — This patent describes a new way to deliver powerful cancer drugs directly to tumor cells using a specific antibody attached to a special polymer, aiming to reduce side effects.
- [Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment](https://patentbrief.org/patent/us/12121527/anthracycline-based-antibody-drug-conjugates-having-high-in-vivo-tolerability) — This patent describes a specific way to build antibody-drug conjugates (ADCs) for cancer treatment by precisely attaching chemotherapy drugs to antibodies to make them safer inside the body.
- [A Chemical Linker for Attaching Drugs to Antibodies](https://patentbrief.org/patent/us/10772965/covalent-linkers-in-antibody-drug-conjugates-and-methods-of-making-and-using-the) — This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.
- [A Stable Recipe for a Cancer-Fighting Antibody Drug](https://patentbrief.org/patent/us/10391181/cyclodextrin-and-antibody-drug-conjugate-formulations) — This patent describes a specific, stable recipe for a cancer-fighting antibody-drug conjugate (ADC) that targets CD33, using cyclodextrin and a lyoprotectant to keep it effective and reduce impurities.
